Bloom Bernard S, Chhatre Sumedha, Jayadevappa Ravi
University of Pennsylvania, Department of Medicine, Division of Geriatrics, Pennsylvania, USA.
Am J Alzheimers Dis Other Demen. 2004 Jul-Aug;19(4):226-32. doi: 10.1177/153331750401900406.
A retrospective cohort control study of three populations, 65 years of age or older, at the same institution estimated the incremental cost of Alzheimer's disease (AD). The AD population of the ambulatory Alzheimer's Disease Center (ADC) (n = 640) was matched by age, gender, ethnicity, and address to one with AD from the general internal medicine practice (AD-GM) (n = 419) and to a control group without AD (n = 5331)from the same general medicine practice. Medicare costs of all care for all diagnoses were obtained for 1998 and 1999. Mean per person annual Medicare costs were $19,418 for ADC, $18, 753 for AD-GM, and $12,085 for the control group. Incremental cost for ADC population was $7,333 and $6,668 for AD-GM population compared with the control group. Incremental cost was $665 (9.1 percent) higher for ADC than AD-GM. Higher non-AD hospitalizations and length of stay (LOS) by AD populations were the main cost drivers.
在同一机构对三个65岁及以上人群进行的一项回顾性队列对照研究估计了阿尔茨海默病(AD)的增量成本。流动阿尔茨海默病中心(ADC)的AD人群(n = 640)按年龄、性别、种族和地址与普通内科诊所的AD人群(AD-GM)(n = 419)以及同一普通内科诊所的无AD对照组(n = 5331)进行匹配。获取了1998年和1999年所有诊断的所有护理的医疗保险费用。ADC人群的人均年度医疗保险费用为19418美元,AD-GM人群为18753美元,对照组为12085美元。与对照组相比,ADC人群的增量成本为7333美元,AD-GM人群为6668美元。ADC的增量成本比AD-GM高665美元(9.1%)。AD人群较高的非AD住院率和住院时间(LOS)是主要的成本驱动因素。